Protein tyrosine phosphatase inhibitors block myeloid signal transduction through the Fc gamma RI receptor.
Fc-receptor stimulation in certain myeloid cells results in an increase in oxygen consumption termed the respiratory burst. In this report we examine the effects of protein tyrosine phosphatase inhibitors on the Fc gamma receptor-induced myeloid respiratory burst. Antiphosphotyrosine immunoblotting of neutrophils stimulated with opsonized oil particles shows that Fc-receptor stimulation is associated with the tyrosine phosphorylation of cellular proteins. Pretreatment of neutrophils for 10 min with vanadate or phenylarsine oxide (PAO), protein tyrosine phosphatase inhibitors, augments tyrosine phosphorylation in response to Fc-receptor stimulation. Vanadate and PAO inhibit the respiratory burst in a dose-dependent fashion, but have no effect on Fc gamma receptor-mediated phagocytosis, suggesting that the inhibition of the respiratory burst is not due to a general inhibition of Fc gamma-receptor signaling. Neutrophil phagolysosomal membranes were isolated from vanadate-treated and control neutrophils after Fc-receptor stimulation show a reduction in protein tyrosine phosphatase activity and a reduction in the NADPH-dependent oxidase activity and contain greater amounts of phosphotyrosine, relative to control membranes. Vanadate did not inhibit the NADPH-oxidase directly or interfere with the superoxide assay. Vanadate and PAO also inhibited the respiratory burst of interferon-differentiated U937 cells in response to immune complex and Fc gamma RI crosslinking. Pretreatment of U937 cells with PAO completely blocks the serine phosphorylation of the gamma subunit of the Fc gamma R, a response that is associated with Fc gamma RI-receptor activation. The data supports the recent observation that CD45 modulates signal transduction through the Fc gamma RI receptor, suggesting that protein tyrosine phosphatases play a positive modulatory role in the signal relay pathway(s) involving the myeloid Fc gamma RI receptor, resulting in the phosphorylation of the gamma subunit and the activation of the NADPH-oxidase complex.
Durden
D L
DL
Neil Bogart Memorial Laboratories, Department of Pediatrics, Childrens Hospital Los Angeles, University of Southern California School of Medicine 90027.
Rosen
H
H
Michel
B R
BR
Cooper
J A
JA
D000595:Amino Acid Sequence; D001152:Arsenicals / Q000494:pharmacology*; D001853:Bone Marrow / Q000473:pathology* / Q000502:physiology / Q000648:ultrastructure; D002478:Cells, Cultured; D006801:Humans; D008854:Microscopy, Electron; D008969:Molecular Sequence Data; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors; D019255:NADPH Oxidases; D009504:Neutrophils / Q000166:cytology / Q000502:physiology / Q000648:ultrastructure; D010084:Oxidation-Reduction; D010101:Oxygen Consumption / Q000502:physiology; D010766:Phosphorylation; D011233:Precipitin Tests; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors*; D017452:Receptors, IgG / Q000032:analysis / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000378:metabolism; D014638:Vanadates / Q000494:pharmacology*
D001152:Arsenicals; D017452:Receptors, IgG; C029341:oxophenylarsine; D014638:Vanadates; D014443:Tyrosine; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; D017027:Protein Tyrosine Phosphatases